Emergent BioSolutions is a biopharmaceutical company headquartered in Rockville, Md. It develops, manufactures and commercializes a range of immunobiotics, including vaccines and therapeutics. Its BioThrax vaccine, approved by the Food and Drug Administration, is used for the prevention of anthrax infection. The company s commercial business focuses on immunobiotics that are used against infectious diseases and other medical conditions. Its commercial portfolio includes vaccines for hepatitis, meningitis and typhoid disorders. Emergent BioSolutions operates various offices in Singapore, Germany and the United Kingdom. It also maintains a network of third-party marketing representatives in the Middle East, Turkey, India, Australia and several Scandinavian countries in Europe.